# A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

> **NCT04975308** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 874 (actual)

## Conditions studied

- Breast Neoplasms
- Neoplasm Metastasis

## Interventions

- **DRUG:** Imlunestrant
- **DRUG:** Exemestane
- **DRUG:** Fulvestrant
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT04975308
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-10-04
- **Primary completion:** 2024-06-24
- **Final completion:** 2027-08
- **Target enrollment:** 874 (ACTUAL)
- **Last updated:** 2025-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04975308

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04975308, "A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04975308. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*